Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 4/20 | 0.53 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9307489 | 0.88 | S1PR1 (0.57) | SMPD1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL9307491 | 0.88 | S1PR2 (0.57) | SMPD1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL5093658 | 0.85 | PTPN11 (0.66) | S1PR2S1PR1S1PR3LPAR2PTPN1 | |
| SCHEMBL5138907 | 0.85 | PTPN11 (0.66) | S1PR2S1PR1S1PR3LPAR2PTPN1 | |
| SCHEMBL15270922 | 0.84 | THRA (0.52) | SMPD1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL9306342 | 0.84 | S1PR2 (0.53) | SMPD1S1PR2S1PR1S1PR3LPAR2 | |
| SCHEMBL28538873 | 0.83 | MAPT (0.58) | — | |
| SCHEMBL28538792 | 0.83 | MAPT (0.58) | — | |
| SCHEMBL28534185 | 0.83 | MAPT (0.58) | — | |
| SCHEMBL28601211 | 0.83 | ALDH1A1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348017-B2 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2008-03-25 | — | — | US | disclosed |
| EP-1422224-B1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | SHISEIDO CO LTD (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | SHISEIDO CO., LTD. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422224-A1 | DITHIAZOLE COMPOUNDS, MATRIX METALLOPROTEASE INHIBITORS AND EXTERNAL PREPARATIONS FOR THE SKIN | Shiseido Co., Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236111-A1 | Dithiazole compounds, matrix metalloprotease inhibitors and external preparations for the skin | MMP1, MMP2, MMP3 | SMPD1 173/4885S1PR2 2652/4885S1PR1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.